Canertinib dihydrochloride

Suppliers

Names

[ CAS No. ]:
289499-45-2

[ Name ]:
Canertinib dihydrochloride

[Synonym ]:
N-{4-[(3-Chloro-4-fluorophenyl)amino]-7-[3-(morpholin-4-yl)propoxy]quinazolin-6-yl}acrylamide dihydrochloride
Canertinib dihydrochloride
2-Propenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]-6-quinazolinyl]-, hydrochloride (1:2)
Canertinib HCl
N-{4-[(3-chloro-4-fluorophenyl)amino]-7-[3-(morpholin-4-yl)propoxy]quinazolin-6-yl}prop-2-enamide dihydrochloride
CI103
Canertinib (dihydrochloride)
N-{4-[(3-Chloro-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]-6-quinazolinyl}acrylamide dihydrochloride

Chemical & Physical Properties

[ Density]:
1.355g/cm3

[ Boiling Point ]:
691ºC at 760mmHg

[ Melting Point ]:
188-190℃

[ Molecular Formula ]:
C24H27Cl3FN5O3

[ Molecular Weight ]:
558.860

[ Flash Point ]:
371.7ºC

[ Exact Mass ]:
557.116333

[ PSA ]:
88.61000

[ LogP ]:
6.07940

[ Vapour Pressure ]:
6.08E-19mmHg at 25°C

[ Index of Refraction ]:
1.649

[ Storage condition ]:
?20°C

[ Water Solubility ]:
DMSO: >10mg/mL

Safety Information

[ Symbol ]:

GHS07

[ Signal Word ]:
Warning

[ Hazard Statements ]:
H315-H319-H335

[ Precautionary Statements ]:
P261-P305 + P351 + P338

[ Hazard Codes ]:
Xi

[ Risk Phrases ]:
36/37/38

[ Safety Phrases ]:
26

[ RIDADR ]:
NONH for all modes of transport

[ RTECS ]:
UC6316110

Articles

Breast cancer cells can switch between estrogen receptor alpha and ErbB signaling and combined treatment against both signaling pathways postpones development of resistance.

Breast Cancer Res. Treat. 121(3) , 601-13, (2010)

The majority of breast cancers are estrogen responsive, but upon progression of disease other growth promoting pathways are activated, e.g., the ErbB receptor system. The present study focuses on resi...

A multivariate model of ErbB network composition predicts ovarian cancer cell response to canertinib.

Biotechnol. Bioeng. 109(1) , 213-24, (2012)

Identifying the optimal treatment strategy for cancer is an important challenge, particularly for complex diseases like epithelial ovarian cancer (EOC) that are prone to recurrence. In this study we d...

Differential action of small molecule HER kinase inhibitors on receptor heterodimerization: therapeutic implications.

Int. J. Cancer 131(1) , 244-52, (2012)

Deregulation of ErbB/HER receptor tyrosine kinases has been linked to several types of cancer. The mechanism of activation of these receptors includes establishment of receptor dimers. Here, we have a...


More Articles

Related Compounds

  • Canertinib (CI-1033)
  • Quinpirole dihydrochloride
  • Benzylhydrazine dihydrochloride
  • benzidine dihydrochloride
  • Furosine dihydrochloride
  • Cyclobutylhydrazine dihydrochloride
  • 4-((Cyclohexylamino)methyl)benzoic acid hydrochloride
  • 1-[(2,4-Dichlorophenyl)methyl]-N-(1,1-dimethylethyl)-2-methyl-1H-indole-3-methanamine
  • 2-(2-((4-bromobenzyl)thio)-5-(hydroxymethyl)-1H-imidazol-1-yl)-N-cyclopentylacetamide
  • 2-Methoxy-6-(pyrazol-1-yl)-benzonitrile
  • 1H-3-Benzazepin-7-ol, 8-chloro-2,3,4,5-tetrahydro-5-(3-iodophenyl)-3-methyl-, (S)-
  • (4-Methyl-tetrahydro-furan-2-yl)-methanol
  • N-(1-cyanocyclopentyl)-2-[4-(4-fluorobenzenesulfonyl)-1,4-diazepan-1-yl]acetamide
  • 4,5,6,7-Tetrahydrobenzo[d]isoxazole-3-carbaldehyde
  • tert-Butyl-DL-alanine
  • 6-Cyano-9,10-didehydroergolinecarboxylic acid methyl ester